NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Forecast, Price & News

$13.57

-0.14 (-1.02%)

(As of 09/29/2023 ET)

Compare

Today's Range: $13.19
▼
$13.82
50-Day Range: $12.90
▼
$17.45
52-Week Range: $12.29
▼
$30.79

Volume: 34,667 shs
Average Volume: 68,723 shs
Market Capitalization: $375.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.00

Aerovate Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 172.7% Upside
$37.00 Price Target
Short Interest: Bearish
8.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: Selling Shares
$750,605 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.82) to ($2.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

789th out of 970 stocks

Pharmaceutical Preparations Industry

374th out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
Aerovate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.00, Aerovate Therapeutics has a forecasted upside of 172.7% from its current price of $13.57.
Amount of Analyst Coverage
Aerovate Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.29% of the float of Aerovate Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aerovate Therapeutics has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.
Change versus previous month
Short interest in Aerovate Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aerovate Therapeutics does not currently pay a dividend.
Dividend Growth
Aerovate Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVTE.

3.0

News and Social Media Coverage

News Sentiment
Aerovate Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aerovate Therapeutics this week, compared to 1 article on an average week.
Search Interest
2 people have searched for AVTE on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $750,605.00 in company stock.
Percentage Held by Insiders
19.30% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.82) to ($2.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aerovate Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aerovate Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aerovate Therapeutics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aerovate Therapeutics (NASDAQ:AVTE) Stock

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE Price History

30 days | 90 days | 365 days | Advanced Chart

AVTE Stock News Headlines

August 14, 2023 | finance.yahoo.com

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

August 14, 2023 | finance.yahoo.com

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

September 30, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

July 11, 2023 | finance.yahoo.com

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

June 28, 2023 | seekingalpha.com

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH

June 23, 2023 | finance.yahoo.com

TENX: Notice of Allowance Increases Confidence

June 22, 2023 | marketwatch.com

8-K: Aerovate Therapeutics, Inc.

May 23, 2023 | msn.com

Peter Kolchinsky-led RA Capital’s New Positions Feature CureVac, Mineralys, Pilant, Enliven Therapeutics

September 30, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 22, 2023 | finance.yahoo.com

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

May 17, 2023 | markets.businessinsider.com

Aerovate Therapeutics (AVTE) Receives a Buy from Wedbush

May 16, 2023 | msn.com

Aerovate Therapeutics GAAP EPS of -$0.67 misses by $0.07

May 16, 2023 | finanznachrichten.de

Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

May 15, 2023 | msn.com

Recap: Aerovate Therapeutics Q1 Earnings

May 15, 2023 | finance.yahoo.com

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

May 15, 2023 | finance.yahoo.com

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

April 12, 2023 | seekingalpha.com

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

March 30, 2023 | finanznachrichten.de

Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

March 29, 2023 | finance.yahoo.com

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

March 9, 2023 | benzinga.com

Aerovate Therapeutics Chief Executive Officer Awarded $3.29M Worth of Stock Options

March 3, 2023 | msn.com

Guggenheim Initiates Coverage of Aerovate Therapeutics (AVTE) with Buy Recommendation

March 2, 2023 | finance.yahoo.com

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

January 23, 2023 | finance.yahoo.com

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

December 31, 2022 | finance.yahoo.com

Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

December 28, 2022 | finance.yahoo.com

12 Best Performing Biotech Stocks in 2022

December 6, 2022 | finance.yahoo.com

Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis

November 17, 2022 | finance.yahoo.com

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

See More Headlines

Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTE Company Calendar

Last Earnings: 8/14/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVTE
CUSIP: N/A
CIK: 1798749
Web: aerovatetx.com
Phone: 617-443-2400
Fax: N/A
Employees: 43
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.00
High Stock Price Forecast: $48.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +172.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.26%
Return on Assets: -45.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.48
Quick Ratio: 11.48

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.19 per share
Price / Book: 2.61

Miscellaneous

Outstanding Shares: 27,650,000
Free Float: 22,314,000
Market Cap: $375.21 million
Optionable: Not Optionable
Beta: 0.37

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Timothy P. Noyes M.B.A. (Age 61)
CEO & Director
Comp: $703.8k

Mr. George A. Eldridge (Age 60)
CFO & Treasurer
Comp: $533.89k

Dr. Marinus Verwijs Ph.D. (Age 47)
Chief Technical Officer
Comp: $439.88k

Dr. Benjamin T. Dake Ph.D. (Age 47)
Founder, Pres, COO & Sec.

Dr. Ralph W. Niven M.B.A. (Age 63)
M.R, Ph.D., Pharm.S, Chief Scientific Officer

Mr. Hunter Gillies M.D. (Age 57)
Chief Medical Officer

Mr. Timothy J. Pigot (Age 52)
Chief Commercial Officer

Ms. Donna Dea
Head of Regulatory Affairs

Ms. Susan Fischer
Sr. VP of Devel. Operations

Mr. Stephen K. Yu
Sr. VP of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVTE Stock - Frequently Asked Questions

Should I buy or sell Aerovate Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVTE shares.
View AVTE analyst ratings or view top-rated stocks.
What is Aerovate Therapeutics' stock price forecast for 2023?: 3 equities research analysts have issued 12 month target prices for Aerovate Therapeutics' shares. Their AVTE share price forecasts range from $27.00 to $48.00. On average, they predict the company's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price.
View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts.
How have AVTE shares performed in 2023?: Aerovate Therapeutics' stock was trading at $29.30 at the beginning of 2023. Since then, AVTE shares have decreased by 53.7% and is now trading at $13.57.
View the best growth stocks for 2023 here.
Are investors shorting Aerovate Therapeutics?: Aerovate Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,430,000 shares, an increase of 5.9% from the August 31st total of 1,350,000 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is currently 20.0 days. Approximately 8.3% of the company's shares are sold short.
View Aerovate Therapeutics' Short Interest.
When is Aerovate Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our AVTE earnings forecast.
How were Aerovate Therapeutics' earnings last quarter?: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.07.

When did Aerovate Therapeutics IPO?: (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.
What is Aerovate Therapeutics' stock symbol?: Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE."
How do I buy shares of Aerovate Therapeutics?: Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aerovate Therapeutics' stock price today?: One share of AVTE stock can currently be purchased for approximately $13.57.
How much money does Aerovate Therapeutics make?: Aerovate Therapeutics (NASDAQ:AVTE) has a market capitalization of $375.21 million. The company earns $-51,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.
How can I contact Aerovate Therapeutics?: The official website for the company is aerovatetx.com. The company can be reached via phone at 617-443-2400 or via email at ir@aerovatetx.com.

This page (NASDAQ:AVTE) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial